7 years ago

Artios Pharma Raises $84m in Series B Financing for Cancer Treatments

  • Artios Pharma, a Cambridge-based DNA Damage Response company, has raised $84m (£65m) in a Series B financing led by Andera Partners and LSP

  • The funds will be used to advance its small molecule DDR programs through clinical proof of concept trials.

      • ProblemHealthcare

      "Cancer cells repair DNA damage by activating DNA damage response pathway, making them harder to kill with chemotherapy and radiotherapy."

      Solution

      "Artios Pharma is developing innovative treatments by inhibiting novel DNA repair targets like Polθ, selectively killing cancer cells without harming normal cells, allowing for use in monotherapy or combination with existing cancer therapies."

      Covered on